



STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 104472

TO: Christine Saoud
Location: CM1/10E03&10B19
Art Unit: 1647
Thursday, September 25, 2003

Case Serial Number: 09/905348

From: Barb O'Bryen
Location: Biotech-Chem Library
CM1-6A05
Phone: 308-4291

BOB
barbara.obryen@uspto.gov

Search Notes

RUSH

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM protein - protein search, using sw model

Run on: September 24, 2003, 18:05:48 ; Search time 41 Seconds

(without alignments)
731.691 Million cell updates/sec

Title: US-09-905-348-18

Perfect score: 1045

Sequence: 1 MHTRTTWARTSRAVTPC.....QVSVSPAPSRGALRRRA 189

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 1107863 segs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 08

Maximum Match 1008

Listing first 45 summaries

Database : A.GeneSeq.19jun03.*

- 1: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1980.DAT.*
- 2: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1981.DAT.*
- 3: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1982.DAT.*
- 4: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1983.DAT.*
- 5: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1984.DAT.*
- 6: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1985.DAT.*
- 7: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1986.DAT.*
- 8: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1987.DAT.*
- 9: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1988.DAT.*
- 10: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1989.DAT.*
- 11: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1990.DAT.*
- 12: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1991.DAT.*
- 13: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1992.DAT.*
- 14: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1993.DAT.*
- 15: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1994.DAT.*
- 16: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1995.DAT.*
- 17: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1996.DAT.*
- 18: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1997.DAT.*
- 19: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1998.DAT.*
- 20: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA1999.DAT.*
- 21: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA2000.DAT.*
- 22: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA2001.DAT.*
- 23: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA2002.DAT.*
- 24: /SIDSI/gcgdata/geneSeq/geneSeq-emb1/AA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	1045	100.0	189	22	AAB80215 Human PRO232 prote
2	1045	100.0	189	24	ABU69625 Novel human secret
3	1045	100.0	189	24	ABU71448 Human PRO polypept
4	1045	100.0	189	24	ABU71894 Human secreted/tra
5	1045	100.0	189	24	ABU67348 Human secreted pro
6	1045	100.0	189	24	ABU64502 Human secreted/tra
7	1045	100.0	189	24	ABU54350 Human secreted/tra
8	998	95.5	187	20	AAV66174 Human bladder tumo
9	119	11.4	1518	24	AB18375 Breast specific re

10	117.5	11.2	277	22	ABU53162 Human testes-deriv
11	117.5	11.2	368	22	ABU53157 Human testes-deriv
12	117.5	11.2	385	22	ABU53156 Human testes-deriv
13	117.5	11.2	386	22	ABU53159 Human testes-deriv
14	117.5	11.2	387	22	ABU53161 Human testes-deriv
15	117.5	11.2	395	22	ABU53160 Human testes-deriv
16	117.5	11.2	5179	22	AAW24514 Human testes-deriv
17	117.5	11.2	5179	22	AAW24516 Human testes-deriv
18	117.5	11.2	5179	24	ABP53655 Human colon tumour
19	115.5	11.1	1008	22	ABH11527 Human apolipoprote
20	115.5	11.1	1013	22	ABG08112 Novel human diago
21	114.5	11.0	1247	24	ABU25815 Aspergillus fumiga
22	114.5	11.0	1263	24	ABU26415 Aspergillus fumiga
23	114.5	10.9	1040	22	ABG14734 Novel human diago
24	111.5	10.7	1012	20	AAV17406 Human atrophin-1 r
25	111.5	10.7	1488	23	ABG97476 Human NAAP1, from
26	111.5	10.7	1568	23	ABG97467 Human NAAP1, from
27	109.5	10.5	693	23	ABP69529 Human polypeptide
28	108	10.3	2009	22	ABG06085 Novel human diago
29	107.5	10.3	199	23	AAO21814 Lung-specific amin
30	106.5	10.2	351	22	ABG26338 Protonibacterium
31	106	10.1	372	22	AAU48589 Streptomyces virid
32	104.5	10.0	19938	24	ABF76679 Human OREF ORF95
33	104	10.0	692	22	ABU53155 Cotton fiber-speci
34	104	10.0	2971	21	AAAB41231 Mouse neutral Mena+
35	103.5	9.9	214	17	AAAB6913 Mouse neutral Mena+
36	103.5	9.9	783	19	AAW37152 Mouse neutral Mena+
37	103.5	9.9	802	19	AAW37153 Mouse neutral Mena+
38	103.5	9.9	802	19	AAW37153 Mammalian enabled
39	103.5	9.9	802	22	ABU09139 Human prostate spe
40	103	9.9	872	23	AAU98904 Human NOV polypep
41	103	9.9	1006	24	ABU54583 Human protein SEQ
42	103	9.9	1328	22	AAW78519 Human protein SEQ
43	103	9.9	1331	22	AAW79503 Human protein
44	103	9.9	1331	22	AAW79503 HHV8 ORF 73 protei
45	100.5	9.6	1162	21	

ALIGNMENTS

RESULT 1	
AAB80215	standard; Protein; 189 AA.
ID	
AC	AAB80215;
XX	
DT	24-APR-2001 (first entry)
DE	Human PRO232 protein.
DE	
XX	Human: PRO; dermatological; antiproliferative; cytosolic; antinflammatory;
KW	antiparkinsonian neurotrophic; neuroprotective; vulnerrary; cardiant;
KW	antiangiogenic; vasotrophic; antiaesthetic; antithematic; cancer;
KW	antiarthritic; antiferility; antidiabetic; antitumor; diabetes;
KW	ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW	ischemia; inflammation.
XX	
OS	Homo sapiens.
XX	
PN	WO200104311-A1.
XX	
PD	18-JAN-2001.
XX	
PF	22-FEB-2000; 2000WO-US04414.
XX	
PR	07-JUL-1999; 99US-0143048.
XX	
PR	26-JUL-1999; 99US-0145698.
XX	
PR	28-JUL-1999; 99US-0146222.
XX	
PR	08-SEP-1999; 99WO-US20594.
XX	
PR	13-SEP-1999; 99WO-US20944.
XX	
PR	15-SEP-1999; 99WO-US21090.
XX	
PR	15-SEP-1999; 99WO-US21547.

PR 05-OCT-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US28313.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US30999.
 PR 05-JAN-2000; 99WO-US00219.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi AJ, Botstein D, Desnoyers L, Eaton DL, Ferrara N,
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard A,
 PI Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ, Kijavir IJ,
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 DR WPI: 2001-081051/09.
 DR N-PSDB; AAF72374.
 XX
 PT Sixty one nucleic acids encoding PRO polypeptides which are useful in
 PT the treatment of skin diseases (e.g. psoriasis), cancers (e.g. lung
 PT squamous cell carcinoma) and neurodegenerative diseases (e.g.
 PT Alzheimer's disease)
 XX
 PS Claim 1; Fig 9; 39pp; English.
 XX
 CC The present sequence is one of sixty one novel secreted and
 CC transmembrane PRO polypeptides. The PRO polypeptides are
 CC useful for treating skin diseases (e.g. psoriasis), cancers (e.g. lung
 CC squamous cell carcinoma), gastrointestinal disorders (e.g.
 CC enterocolitis), neurodegenerative diseases (e.g. Alzheimer's disease,
 CC Parkinson's disease), wound repair, cardiovascular disorders (e.g.
 CC endometrial bleeding angiogenesis, ischemias such as coronary
 CC ischemia, atherosclerosis), inflammatory disorders (e.g. asthma,
 CC rheumatoid arthritis, multiple sclerosis), infertility, AIDS and
 CC diabetes and retinal disorders such as retinitis pigmentosa.
 CC The PRO nucleic acids have applications in molecular biology, including
 CC use as hybridization probes, and in chromosome and gene mapping.
 XX
 SQ Sequence 189 AA;
 Query Match 100.0%; Score 1045; DB 22; Length 189;
 Best Local Similarity 100.0%; Pred. No. 5.3e-86;
 Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTRHTTWARTRSAVTPCATPAGPMPCSRRLPSRLCSLHSAACSGDPASYRLMGAPLQ 60
 Db 1 MTRHTTWARTRSAVTPCATPAGPMPCSRRLPSRLCSLHSAACSGDPASYRLMGAPLQ 60
 QY 61 PTIGVVPQASVPLTDLAQWEPVLPVPAHPNASLTMVCTPVPHPDPMALSRTPROIS 120
 Db 61 PTIGVVPQASVPLTDLAQWEPVLPVPAHPNASLTMVCTPVPHPDPMALSRTPROIS 120
 QY 121 SSPTDPADGSPNPLCCCFHGFPAFTLNRYLHFPDEAPPAHPYDLSQVSVSPAPS 180
 Db 121 SSPTDPADGSPNPLCCCFHGFPAFTLNRYLHFPDEAPPAHPYDLSQVSVSPAPS 180
 QY 181 RGOALRRARQ 189
 Db 181 RGOALRRARQ 189
 RESULT 2
 AB069625
 ID AB069625 standard; Protein: 189 AA.
 AC AB069625;
 XX
 XX 05-JUN-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO232.
 XX
 KW Human; secreted and transmembrane protein; gene therapy; psoriasis;

KW enterocolitis; gastrointestinal ulceration; skin disease;
 KW keratinocyte differentiation; epithelial cancer; Alzheimer's disease;
 KW squamous cell carcinoma; Parkinson's disease; inflammatory disease;
 KW amyotrophic lateral sclerosis; rheumatoid arthritis; asthma;
 KW multiple sclerosis; organ failure; atherosclerosis; cardiac injury;
 KW infertility; birth defect; premature aging; AIDS; cancer;
 KW diabetic complication; wound repair; tissue re-growth.
 XX
 OS Homo sapiens.
 XX
 XX US2003017463-A1.
 XX
 PD 23-JAN-2003.
 XX
 PF 11-JUL-2001; 2001US-0903640.
 XX
 XX 10-SEP-1998; 98WO-US18824.
 XX 14-SEP-1998; 98WO-US19177.
 XX 16-SEP-1998; 98WO-US19330.
 XX 17-SEP-1998; 98WO-US19437.
 XX 01-DEC-1998; 98WO-US25108.
 XX 08-SEP-1999; 99WO-US20594.
 XX 13-SEP-1999; 99WO-US20944.
 XX 15-SEP-1999; 99WO-US21090.
 XX 15-SEP-1999; 99WO-US21547.
 XX 05-OCT-1999; 99WO-US23089.
 XX 29-NOV-1999; 99WO-US28214.
 XX 30-NOV-1999; 99WO-US28313.
 XX 01-DEC-1999; 99WO-US28301.
 XX 02-DEC-1999; 99WO-US28565.
 XX 16-DEC-1999; 99WO-US30095.
 XX 20-DEC-1999; 99WO-US30911.
 XX 20-DEC-1999; 99WO-US30999.
 XX 05-JAN-2000; 2000WO-US00219.
 XX 11-FEB-2000; 2000WO-US03565.
 XX 22-FEB-2000; 2000WO-US04414.
 XX 24-FEB-2000; 2000WO-US05004.
 XX 02-MAR-2000; 2000WO-US05841.
 XX 20-MAR-2000; 2000WO-US07377.
 XX 30-MAR-2000; 2000WO-US08439.
 XX 22-MAY-2000; 2000WO-US14042.
 XX 02-JUN-2000; 2000WO-US15264.
 XX 28-JUL-2000; 2000WO-US20710.
 XX 24-AUG-2000; 2000WO-US23328.
 XX 17-SEP-1997; 97US-05113P.
 XX 17-SEP-1997; 97US-05115P.
 XX 17-SEP-1997; 97US-05117P.
 XX 17-SEP-1997; 97US-05119P.
 XX 17-SEP-1997; 97US-05121P.
 XX 17-SEP-1997; 97US-05122P.
 XX 17-SEP-1997; 97US-05184P.
 XX 18-SEP-1997; 97US-059263P.
 XX 18-SEP-1997; 97US-059266P.
 XX 15-OCT-1997; 97US-062125P.
 XX 17-OCT-1997; 97US-062285P.
 XX 17-OCT-1997; 97US-062287P.
 XX 21-OCT-1997; 97US-063486P.
 XX 24-OCT-1997; 97US-062814P.
 XX 24-OCT-1997; 97US-062816P.
 XX 24-OCT-1997; 97US-063045P.
 XX 24-OCT-1997; 97US-063120P.
 XX 24-OCT-1997; 97US-063121P.
 XX 24-OCT-1997; 97US-063127P.
 XX 24-OCT-1997; 97US-063128P.
 XX 27-OCT-1997; 97US-063327P.
 XX 27-OCT-1997; 97US-063329P.
 XX 28-OCT-1997; 97US-063541P.
 XX 28-OCT-1997; 97US-063542P.
 XX 28-OCT-1997; 97US-063544P.
 XX 28-OCT-1997; 97US-063549P.
 XX 28-OCT-1997; 97US-063550P.
 XX 28-OCT-1997; 97US-063564P.

PR 29-OCT-1997; 97US-063435P.
 PR 29-OCT-1997; 97US-063704P.
 PR 29-OCT-1997; 97US-063732P.
 PR 29-OCT-1997; 97US-063734P.
 PR 29-OCT-1997; 97US-063735P.
 PR 29-OCT-1997; 97US-063738P.
 PR 29-OCT-1997; 97US-064215P.
 PR 31-OCT-1997; 97US-063870P.
 PR 31-OCT-1997; 97US-064103P.
 PR 03-NOV-1997; 97US-064248P.
 PR 07-NOV-1997; 97US-064809P.
 PR 12-NOV-1997; 97US-065186P.
 PR 17-NOV-1997; 97US-065846P.
 PR 18-NOV-1997; 97US-065932P.
 PR 21-NOV-1997; 97US-066120P.
 PR 21-NOV-1997; 97US-066364P.
 PR 24-NOV-1997; 97US-066453P.
 PR 24-NOV-1997; 97US-066466P.
 PR 24-NOV-1997; 97US-066511P.
 PR 24-NOV-1997; 97US-066702P.
 PR 24-NOV-1997; 97US-066722P.
 PR 25-NOV-1997; 97US-066840P.
 PR 12-DEC-1997; 97US-066842P.
 PR 04-JUN-1998; 98US-068026P.
 PR 10-SEP-1998; 98US-069803P.
 PR 14-SEP-1998; 98US-100262P.
 PR 17-SEP-1998; 98US-100858P.
 PR 13-OCT-1998; 98US-104080P.
 PR 20-NOV-1998; 98US-109304P.
 PR 22-DEC-1998; 98US-113296P.
 PR 07-JUL-1999; 99US-143048P.
 PR 26-JUL-1999; 99US-143698P.
 PR 28-JUL-1999; 99US-146222P.
 PR 18-SEP-2000; 2000US-0665350.
 (GETH) GENENTECH INC.
 PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 XX Filvaroff E, Fong S, Garber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tunnas D;
 PI Williams PM, Wood WI;
 XX WPI; 2003-341586/32.
 DR N-PSDB; ACAS4821.
 DR
 XX
 PT New PRO polypeptides and nucleic acid molecules, useful in diagnosing
 PT or treating inflammatory diseases, organ failure, atherosclerosis,
 PT cardiac injury, infertility, cancer, AIDS, Alzheimer's disease or
 PT Parkinson's disease -
 XX
 XX
 PS Claim 12; Fig 9; 473p; English.
 XX
 XX The invention describes sixty one nucleic acids encoding PRO polypeptides
 CC (secreted and transmembrane). The PRO polypeptides and nucleic acids are
 CC useful in diagnosing or treating enterocolitis, gastrointestinal
 CC ulceration, skin diseases associated with abnormal keratinocyte
 CC differentiation, e.g. psoriasis or epithelial cancers such as squamous
 CC cell carcinoma, Alzheimer's disease, Parkinson's disease, amyotrophic
 CC lateral sclerosis, inflammatory diseases, e.g. rheumatoid arthritis,
 CC asthma or multiple sclerosis, organ failure, atherosclerosis, cardiac
 CC injury, infertility, birth defects, premature aging, AIDS, cancer,
 CC diabetic complications, or mutations in general. The polypeptides are
 CC also useful for wound repair and associated therapies concerned with
 CC re-growth of tissue. The PRO polypeptides and nucleic acid molecules
 CC are also useful in gene therapy, and as molecular weight markers for
 CC protein electrophoresis purposes. The anti-PRO antibodies may be used
 CC in diagnostic assays for PRO, or for the affinity purification of PRO
 CC from recombinant cell culture or natural sources. This is the amino
 CC acid sequence of a novel human PRO polypeptide.
 XX
 SO Sequence 189 AA;

Query Match 100.0%; Score 1045; DB 24; Length 189;
 Best Local Similarity 100.0%; Pred. No. 5,3e-86;
 Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1 MTHRTTARRTSRAVTTTCATPACPMCSRLPSLRCSLSHACCSGDPASTYRLMGAPLQ 60
 Db 1 MTHRTTARRTSRAVTTTCATPACPMCSRLPSLRCSLSHACCSGDPASTYRLMGAPLQ 60
 Oy 61 PTLGVVPOASVPLDLDAWEPVLVPEAHPNASLTMVCTVPHPPPMALSRPTROIS 120
 Db 61 PTLGVVPOASVPLDLDAWEPVLVPEAHPNASLTMVCTVPHPPPMALSRPTROIS 120
 Oy 121 SSDDPPADGSPNPLCCCFHGPAFSTLNPVLRHLPEQAFPAHPPIYDLSQVSVSPAPS 180
 Db 121 SSDDPPADGSPNPLCCCFHGPAFSTLNPVLRHLPEQAFPAHPPIYDLSQVSVSPAPS 180
 Oy 181 RQALRRRAQ 189
 Db 181 RQALRRRAQ 189
 RESULT 3
 ABU71448
 ID ABU71448 standard; Protein; 189 AA.
 AC ABU71448;
 XX
 XX 10-JUN-2003 (first entry)
 DE Human PRO polypeptide #4.
 XX
 XX Human; secreted and transmembrane protein; PRO polypeptide; cancer;
 KW Alzheimer's disease; ischemia; cytosolic; neurotropic; vasotropic;
 KW neuroprotective.
 OS Homo sapiens.
 XX
 XX US2002192659-A1.
 PD 19-DEC-2002.
 XX
 XX 10-JUL-2001; 2001US-0902853.
 FE
 XX 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19177.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 01-DEC-1998; 98WO-US25108.
 PR 08-SEP-1999; 99WO-US20594.
 PR 13-SEP-1999; 99WO-US20944.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 05-OCT-1999; 99WO-US23089.
 PR 01-DEC-1999; 99WO-US28301.
 PR 02-DEC-1999; 99WO-US28564.
 PR 16-DEC-1999; 99WO-US28565.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US30999.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 17-SEP-1997; 97US-059113P.
 PR 17-SEP-1997; 97US-059115P.
 PR 17-SEP-1997; 97US-059117P.
 PR 18-SEP-1997; 97US-059266P.
 PR 15-OCT-1997; 97US-062125P.
 PR 17-OCT-1997; 97US-062285P.
 PR 17-OCT-1997; 97US-062287P.
 PR 21-OCT-1997; 97US-063486P.
 PR 24-OCT-1997; 97US-062814P.

PR 24-OCT-1997; 97US-062816P.
XX
PA (GETH) GENENTECH INC.
PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
PI Filvaroff E, Fong S, Gao W, Garber H, Gerritsen ME, Goddard A;
PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavini IJ;
PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
PI Williams PM, Wood WI;
XX
XX WPI: 2003-361832/34.
DR N-PSDB: ACAS8306.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO245 or
PT PRO1868, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy
XX
PS Claim 12; Fig 9; 474pp; English.
XX
XX The present invention relates to the isolation of novel human secreted
XX and transmembrane proteins (PRO polypeptides), and the polynucleotide
XX sequences encoding them. The polynucleotide sequences are useful in
XX molecular biology, as hybridisation probes, in chromosome and gene
XX mapping, in generating antisense RNA and DNA, and in gene therapy. The
XX polynucleotide sequences may also be used in preparing PRO polypeptides
XX or knock-out animals which, in turn, are useful in the development and
XX screening of therapeutically useful reagents. The PRO polypeptides or
XX their antibodies are useful in preparing a medicament for treating a
XX condition responsive to the polypeptide or antibody, such as cancer,
XX Alzheimer's disease or ischaemia, and in various diagnostic assays.
XX ABU71445-ABU71505 represent human PRO polypeptides of the invention.
SQ Sequence 189 AA;

Query Match 100.0%; Score 1045; DB 24; Length 189;
Best Local Similarity 100.0%; Pred. No. 5,3e-86;
Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 MTRHTTWMARTSRAVPTCATPPAGPMPGSRPLPSLSCSHSACCSGDPASYRLMGAPLQ 60
DB 1 MTRHTTWMARTSRAVPTCATPPAGPMPGSRPLPSLSCSHSACCSGDPASYRLMGAPLQ 60
QY 61 PTIGVVPQASVPLITDLAQWEPVLVPEAHNASTLTMVCTPVPHDPDPALSTRPTROIS 120
DB 61 PTIGVVPQASVPLITDLAQWEPVLVPEAHNASTLTMVCTPVPHDPDPALSTRPTROIS 120
QY 121 SSPTDPPADGSPNPLCCCFHGFAPSTNPTLRLHFPQEARPAHPITDLSQWVSVPAPS 180
DB 121 SSPTDPPADGSPNPLCCCFHGFAPSTNPTLRLHFPQEARPAHPITDLSQWVSVPAPS 180
QY 181 RGOALRRRAQ 189
DB 181 RGOALRRRAQ 189

RESULT 4
ABU71894
ID ABU71894 standard; Protein; 189 AA.
XX
AC ABU71894;
XX
DT 12-JUN-2003 (first entry)
XX
XX Human secreted/transmembrane protein PRO232.
XX
XX Human; secreted protein; transmembrane protein; PRO;
KM gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003003530-A1.
XX

PD 02-JAN-2003.
XX
XX 11-JUL-2001; 2001US-0904011.
XX
XX 10-SEP-1998; 98WO-US18824.
PR 14-SEP-1998; 98WO-US19177.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 01-DEC-1998; 98WO-US25108.
PR 08-SEP-1999; 99WO-US20594.
PR 13-SEP-1999; 99WO-US20944.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 05-OCT-1999; 99WO-US23069.
PR 29-NOV-1999; 99WO-US28214.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 02-DEC-1999; 99WO-US28564.
PR 16-DEC-1999; 99WO-US28565.
PR 20-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 99WO-US30999.
PR 11-FEB-2000; 2000WO-US00219.
PR 22-FEB-2000; 2000WO-US03565.
PR 24-FEB-2000; 2000WO-US04414.
PR 02-MAR-2000; 2000WO-US05004.
PR 20-MAR-2000; 2000WO-US05841.
PR 30-MAR-2000; 2000WO-US07377.
PR 22-MAY-2000; 2000WO-US08439.
PR 02-JUN-2000; 2000WO-US14042.
PR 28-JUL-2000; 2000WO-US15264.
PR 24-AUG-2000; 2000WO-US20710.
PR 17-SEP-1997; 97US-0581328.
PR 17-SEP-1997; 97US-058113P.
PR 17-SEP-1997; 97US-059115P.
PR 17-SEP-1997; 97US-059117P.
PR 17-SEP-1997; 97US-059119P.
PR 17-SEP-1997; 97US-059121P.
PR 17-SEP-1997; 97US-059122P.
PR 17-SEP-1997; 97US-059184P.
PR 18-SEP-1997; 97US-059263P.
PR 18-SEP-1997; 97US-059266P.
PR 15-OCT-1997; 97US-062125P.
PR 17-OCT-1997; 97US-062285P.
PR 21-OCT-1997; 97US-062287P.
PR 21-OCT-1997; 97US-062814P.
PR 24-OCT-1997; 97US-062816P.
PR 24-OCT-1997; 97US-063045P.
PR 24-OCT-1997; 97US-063120P.
PR 24-OCT-1997; 97US-063121P.
PR 24-OCT-1997; 97US-063127P.
PR 24-OCT-1997; 97US-063128P.
PR 27-OCT-1997; 97US-063327P.
PR 27-OCT-1997; 97US-063329P.
PR 28-OCT-1997; 97US-063541P.
PR 28-OCT-1997; 97US-063542P.
PR 28-OCT-1997; 97US-063544P.
PR 28-OCT-1997; 97US-063549P.
PR 28-OCT-1997; 97US-063550P.
PR 28-OCT-1997; 97US-063564P.
PR 28-OCT-1997; 97US-063435P.
PR 29-OCT-1997; 97US-063704P.
PR 29-OCT-1997; 97US-063732P.
PR 29-OCT-1997; 97US-063734P.
PR 29-OCT-1997; 97US-063735P.
PR 29-OCT-1997; 97US-063738P.
PR 29-OCT-1997; 97US-064215P.
PR 31-OCT-1997; 97US-063870P.
PR 31-OCT-1997; 97US-064103P.
PR 03-NOV-1997; 97US-064248P.
PR 07-NOV-1997; 97US-064809P.
PR 12-NOV-1997; 97US-065186P.

PR 17-NOV-1997; 97US-065846P.
 PR 18-NOV-1997; 97US-065693P.
 PR 21-NOV-1997; 97US-066120P.
 PR 21-NOV-1997; 97US-066364P.
 PR 24-NOV-1997; 97US-066453P.
 PR 24-NOV-1997; 97US-066466P.
 PR 24-NOV-1997; 97US-066511P.
 PR 24-NOV-1997; 97US-066770P.
 PR 24-NOV-1997; 97US-066772P.
 PR 18-SEP-2000; 2000US-0665350.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N;
 PI Filvaroff E, Fong S, Gerber H, Gerritsen ME, Goddard A;
 PI Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ, Kijavlin IJ;
 PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WI;
 XX
 DR WPI: 2003-329602/31.
 DR N-PSDB: ACA60013.
 XX
 PT New transmembrane polypeptides and nucleic acids encoding the
 PT polypeptides, useful in gene therapy, in chromosome identification, as
 PT chromosome markers, in generating probes and in tissue typing
 XX
 PS Claim 12; Fig 9; 484pp; English.
 XX
 CC The invention relates to an isolated nucleic acid with at least 80%
 CC nucleic acid sequence identity to a nucleotide sequence encoding one of
 CC 61 secreted/transmembrane polypeptides, or PRO polypeptides or encoding a
 CC PRO protein extracellular domain. Also included are a vector comprising
 CC the PRO nucleic acid, a host cell comprising the vector, producing a PRO
 CC polypeptide (by culturing the host cell for the expression of the PRO
 CC polypeptide, and recovering the PRO polypeptide from the cell culture),
 CC an isolated PRO polypeptide (having at least 80% sequence identity
 CC to: (a) an amino acid sequence selected from the 61 PRO proteins;
 CC (b) an amino acid sequence encoded by a nucleic acid molecule deposited
 CC with an ATCC number (detailed in the specification); or (c) an
 CC extracellular domain of a PRO polypeptide or to a PRO polypeptide lacking
 CC its associated signal peptide), a chimeric molecule comprising a PRO
 CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
 CC antibody, detecting a PRO245 or PRO1868 in a sample suspected of
 CC containing the polypeptide, linking a bioactive molecule to a cell
 CC expressing a PRO245 or PRO1868 and modulating at least one biological
 CC activity of a cell expressing a PRO245 or PRO1868. Nucleic acids which
 CC encode PRO can be used to generate either transgenic animals or knock-out
 CC animals which may be used in the development and screening of
 CC therapeutically useful reagents. The nucleic acids may also be used in
 CC gene therapy, in chromosome identification, as chromosome markers, or in
 CC generating probes. The PRO polypeptides are useful as molecular markers
 CC for protein electrophoresis, and the isolated nucleic acids may be used
 CC for recombinantly expressing those markers. The PRO polypeptides and
 CC nucleic acids may also be used in tissue typing. Anti-PRO antibodies
 CC are useful in diagnostic assays for PRO, and in affinity purification
 CC of PRO from recombinant cell culture or natural sources. The
 CC present sequence represents a PRO protein.
 XX
 SQ Sequence 189 AA:
 Query Match 100.0%; Score 1045; DB 24; Length 189;
 Best Local Similarity 100.0%; Pred. No. 5.3e-86;
 Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

DB 121 SSDTDPADGSPNPLCCCFHGPASTLNPVLRLHLPQEAFAHPHPIYDLSQVSVSPAPS 180
 OY 181 RQQAIRRAQ 189
 DB 181 RQQAIRRAQ 189
 RESULT 5
 AB067348
 ID AB067348 standard; Protein; 189 AA.
 XX
 AC AB067348;
 XX
 DT 29-MAY-2003 (first entry)
 XX
 DE Human secreted protein PRO232.
 XX
 KW Human; gene therapy; mucosal lesion; ulcer; enterocolitis; skin disease;
 KW psoriasis; cancer; lung cancer; colon cancer; nerve cell disease;
 KW Alzheimer's disease; Parkinson's disease; Usher syndrome; angiogenesis;
 KW atrophla areata; inflammatory disease; asthma; rheumatoid arthritis;
 KW Ischaemia.
 XX
 OS Homo sapiens.
 XX
 PN US2003023054-A1.
 XX
 FD 30-JAN-2003.
 XX
 XX 16-JUL-2001; 2001US-0906742.
 PF 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19177.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 01-DEC-1998; 98WO-US23108.
 PR 08-SEP-1999; 99WO-US20594.
 PR 13-SEP-1999; 99WO-US20944.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 05-OCT-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 02-DEC-1999; 99WO-US28564.
 PR 02-DEC-1999; 99WO-US28565.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 20-DEC-1999; 99WO-US30999.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 17-SEP-1997; 97US-059113P.
 PR 17-SEP-1997; 97US-059115P.
 PR 17-SEP-1997; 97US-059117P.
 PR 17-SEP-1997; 97US-059119P.
 PR 17-SEP-1997; 97US-059121P.
 PR 17-SEP-1997; 97US-059122P.
 PR 17-SEP-1997; 97US-059184P.
 PR 18-SEP-1997; 97US-059263P.
 PR 18-SEP-1997; 97US-059266P.
 PR 15-OCT-1997; 97US-062125P.
 PR 17-OCT-1997; 97US-062285P.
 PR 17-OCT-1997; 97US-062287P.

PR 21-OCT-1997; 97US-063486P.
 PR 24-OCT-1997; 97US-062814P.
 PR 24-OCT-1997; 97US-062816P.
 PR 24-OCT-1997; 97US-063045P.
 PR 24-OCT-1997; 97US-063120P.
 PR 24-OCT-1997; 97US-063121P.
 PR 24-OCT-1997; 97US-063127P.
 PR 24-OCT-1997; 97US-063128P.
 PR 27-OCT-1997; 97US-063327P.
 PR 27-OCT-1997; 97US-063329P.
 PR 28-OCT-1997; 97US-063541P.
 PR 28-OCT-1997; 97US-063542P.
 PR 28-OCT-1997; 97US-063544P.
 PR 28-OCT-1997; 97US-063549P.
 PR 28-OCT-1997; 97US-063550P.
 PR 28-OCT-1997; 97US-063564P.
 PR 29-OCT-1997; 97US-063435P.
 PR 29-OCT-1997; 97US-063704P.
 PR 29-OCT-1997; 97US-063732P.
 PR 29-OCT-1997; 97US-063734P.
 PR 29-OCT-1997; 97US-063735P.
 PR 29-OCT-1997; 97US-063738P.
 PR 29-OCT-1997; 97US-064215P.
 PR 31-OCT-1997; 97US-063870P.
 PR 31-OCT-1997; 97US-064103P.
 PR 03-NOV-1997; 97US-064248P.
 PR 07-NOV-1997; 97US-064809P.
 PR 12-NOV-1997; 97US-065186P.
 PR 17-NOV-1997; 97US-065846P.
 PR 18-NOV-1997; 97US-065693P.
 PR 21-NOV-1997; 97US-066120P.
 PR 21-NOV-1997; 97US-066364P.
 PR 24-NOV-1997; 97US-066453P.
 PR 24-NOV-1997; 97US-066466P.
 PR 24-NOV-1997; 97US-066511P.
 PR 24-NOV-1997; 97US-066770P.
 PR 24-NOV-1997; 97US-066772P.
 PR 25-NOV-1997; 97US-066840P.
 PR 12-DEC-1997; 97US-069425P.
 PR 04-JUN-1998; 98US-088026P.
 PR 10-SEP-1998; 98US-099803P.
 PR 14-SEP-1998; 98US-100262P.
 PR 17-SEP-1998; 98US-100858P.
 PR 13-OCT-1998; 98US-104080P.
 PR 20-NOV-1998; 98US-109304P.
 PR 22-DEC-1998; 98US-113296P.
 PR 07-JUL-1999; 99US-143048P.
 PR 26-JUL-1999; 99US-145698P.
 PR 28-JUL-1999; 99US-146222P.
 PR 18-SEP-2000; 2000US-0665350.
 XX
 XX (GETH) GENENTECH INC.
 XX
 PI Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,
 PI Filvaroff E, Fong S, Gao W, Gerber H, Gerritsen ME, Goddard N,
 PI Godowski PJ, Grimaldi JC, Gutney AL, Hillan KJ, Kijavlin IJ,
 PI Mather JP, Pan U, Paoni NF, Roy MA, Stewart TA, Tumas D,
 PI Williams PM, Wood WI;
 XX
 DR WPI: 2003-331485/31.
 DR N-PSDB; ACA05351.
 XX
 PT Sixty one isolated nucleic acids encoding a PRO polypeptide, e.g.
 PT PRO245 or PRO1868, useful in chromosome and gene mapping, in generating
 PT antisense RNA and DNA, and in treating cancer and Alzheimer's disease -
 XX
 XX Example 4; Fig 9; 481pp; English.
 CC The invention relates to sixty one nucleic acids encoding PRO
 CC polypeptides (secreted and transmembrane). The polynucleotide is useful
 CC in molecular biology, including uses as hybridisation probes, in
 CC chromosome and gene mapping, in generating antisense RNA and DNA, and in
 CC gene therapy. The polynucleotide may also be used in preparing PRO

CC polypeptides by recombinant techniques, and in generating either
 CC transgenic animals or knock-out animals which, in turn, are useful in the
 CC development and screening of therapeutically useful reagents. The PRO
 CC polypeptide or the antibody is used in preparing a medicament for
 CC treating a condition responsive to the polypeptide or antibody, such as
 CC mucosal lesions e.g. ulcers and enterocolitis, skin disease e.g.
 CC psoriasis, cancer e.g. lung cancer and colon cancer, nerve cell disease
 CC e.g. Alzheimer's disease and Parkinson's disease, Usher syndrome,
 CC atrophla areata, angioedema, inflammation, inflammatory disease e.g. asthma and
 CC rheumatoid arthritis, ischaemia, and in various diagnostic assays. The
 CC present sequence represents the amino acid sequence of a PRO polypeptide.
 XX
 SQ Sequence 189 AA;
 Query Match 100.0%; Score 1045; DB 24; Length 189;
 Best Local Similarity 100.0%; Pred. No. 5; 3e-86;
 Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTHRTTWARTRSAVPTGCTAPGPMCSRLPRLCSLHSCSCSDPASYRLMGAPLQ 60
 DB 1 MTHRTTWARTRSAVPTGCTAPGPMCSRLPRLCSLHSCSCSDPASYRLMGAPLQ 60
 QY 61 PTLGVPAQASVPLLTDLAQMPEVLPVPAHNASLITMYCTPVPHPDPMALSTRPPOIS 120
 DB 61 PTLGVPAQASVPLLTDLAQMPEVLPVPAHNASLITMYCTPVPHPDPMALSTRPPOIS 120
 QY 121 SSTDPDPADGSPNPLCCCFHGPASTINPVLRHLFQEAEPAPHPIYDLQVMSVSPAPS 180
 DB 121 SSTDPDPADGSPNPLCCCFHGPASTINPVLRHLFQEAEPAPHPIYDLQVMSVSPAPS 180
 QY 181 RGOALRRAO 189
 DB 181 RGOALRRAO 189
 RESULT 6
 AB064502
 ID AB064502 standard; Protein; 189 AA.
 AC AB064502;
 XX
 DT 13-MAY-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein, #5.
 XX
 KW Human; PRO; secreted; transmembrane; pharmaceutical;
 KW diagnostic; biosensor; bioreactor; therapeutic; hyperplasia;
 KW endometriosis; cancer; tumour; ischaemia; coronary arterial disease;
 KW polycystic kidney disease; renal failure; inflammatory response; asthma;
 KW rheumatoid arthritis; psoriasis; multiple sclerosis; gene therapy;
 KW cytostatic; gynecological; cardiac; nephrotropic; hepatotropic;
 KW antiinflammatory.
 XX
 OS Homo sapiens.
 XX
 PN US2002160374-A1.
 PD 31-OCT-2002.
 XX
 PF 12-JUL-2001; 2001US-0905291.
 XX
 PR 10-SEP-1998; 98WO-US18824.
 PR 14-SEP-1998; 98WO-US19177.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 01-DEC-1998; 98WO-US25108.
 PR 08-SEP-1999; 99WO-US20594.
 PR 13-SEP-1999; 99WO-US20944.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 05-OCT-1999; 99WO-US23089.
 PR 29-NOV-1999; 99WO-US28214.
 PR 30-NOV-1999; 99WO-US28313.

01-DEC-1999: 99WO-US28301.
 PR 02-DEC-1999: 99WO-US28564.
 PR 02-DEC-1999: 99WO-US28565.
 PR 16-DEC-1999: 99WO-US30095.
 PR 20-DEC-1999: 99WO-US30911.
 PR 20-DEC-1999: 99WO-US30999.
 PR 05-JAN-2000: 2000WO-US00219.
 PR 11-FEB-2000: 2000WO-US03565.
 PR 22-FEB-2000: 2000WO-US04414.
 PR 24-FEB-2000: 2000WO-US05004.
 PR 02-MAR-2000: 2000WO-US05841.
 PR 20-MAR-2000: 2000WO-US07377.
 PR 30-MAR-2000: 2000WO-US08439.
 PR 22-MAY-2000: 2000WO-US14042.
 PR 02-JUN-2000: 2000WO-US15264.
 PR 28-JUL-2000: 2000WO-US20710.
 PR 24-AUG-2000: 2000WO-US23328.
 PR 17-SEP-1997: 97US-059113P.
 PR 17-SEP-1997: 97US-059115P.
 PR 17-SEP-1997: 97US-059117P.
 PR 17-SEP-1997: 97US-059119P.
 PR 17-SEP-1997: 97US-059121P.
 PR 17-SEP-1997: 97US-059122P.
 PR 17-SEP-1997: 97US-059184P.
 PR 18-SEP-1997: 97US-059283P.
 PR 18-SEP-1997: 97US-059286P.
 PR 15-OCT-1997: 97US-062125P.
 PR 17-OCT-1997: 97US-062285P.
 PR 17-OCT-1997: 97US-062287P.
 PR 21-OCT-1997: 97US-063486P.
 PR 24-OCT-1997: 97US-062816P.
 PR 24-OCT-1997: 97US-062816P.
 PR 24-OCT-1997: 97US-063045P.
 PR 24-OCT-1997: 97US-063120P.
 PR 24-OCT-1997: 97US-063121P.
 PR 24-OCT-1997: 97US-063127P.
 PR 27-OCT-1997: 97US-063327P.
 PR 27-OCT-1997: 97US-063329P.
 PR 28-OCT-1997: 97US-063541P.
 PR 28-OCT-1997: 97US-063542P.
 PR 28-OCT-1997: 97US-063544P.
 PR 28-OCT-1997: 97US-063549P.
 PR 28-OCT-1997: 97US-063550P.
 PR 28-OCT-1997: 97US-063564P.
 PR 29-OCT-1997: 97US-063435P.
 PR 29-OCT-1997: 97US-063704P.
 PR 29-OCT-1997: 97US-063732P.
 PR 29-OCT-1997: 97US-063734P.
 PR 29-OCT-1997: 97US-063735P.
 PR 29-OCT-1997: 97US-064215P.
 PR 29-OCT-1997: 97US-064215P.
 PR 31-OCT-1997: 97US-063870P.
 PR 03-NOV-1997: 97US-064103P.
 PR 07-NOV-1997: 97US-064288P.
 PR 12-NOV-1997: 97US-064809P.
 PR 17-NOV-1997: 97US-065186P.
 PR 18-NOV-1997: 97US-065846P.
 PR 21-NOV-1997: 97US-065693P.
 PR 21-NOV-1997: 97US-066120P.
 PR 21-NOV-1997: 97US-066364P.
 PR 24-NOV-1997: 97US-066453P.
 PR 24-NOV-1997: 97US-066511P.
 PR 24-NOV-1997: 97US-066772P.
 PR 24-NOV-1997: 97US-066772P.
 PR 18-SEP-2000: 2000US-0665350.
 XX (GETH) GENENTECH INC.
 PA Ashkenazi A, Botstein D, Desnoyers L, Eaton DL, Ferrara N,
 PI Filvaroff E, Fong S, Garber H, Gerritsen ME, Goddard A,
 PI Godowski PJ, Grimaldi JC, Gurney AT, Hillan KJ, Kljavin IJ,

PI Mather JP, Pan J, Paoni NF, Roy MA, Stewart TA, Tumas D;
 PI Williams PM, Wood WT;
 XX WPI: 2003-288105/28.
 DR N-PSDB; ABX96030.
 PT New secreted and transmembrane PRO polypeptides (e.g. PRO533 or PRO245)
 PT and genes encoding them, useful for detecting or treating e.g.
 PT hyperplasia, endometriosis, cancers, ischemia, coronary arterial
 PT disease or inflammations -
 XX Claim 12: Fig 9, 477p; English.
 PS
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC and the nucleic acid encoding them. The polypeptides can be used to
 CC raise antibodies that specifically bind to the PRO polypeptide, for
 CC linking a bioactive molecule to a cell expressing a PRO protein and for
 CC modulating at least one biological activity of a cell. The PRO
 CC polypeptides or polynucleotides are also useful as pharmaceuticals,
 CC diagnostics, biosensors or bioreactors, for detecting or treating e.g.
 CC hyperplasia, endometriosis, cancers (e.g. those involving solid tumours),
 CC ischemia, coronary arterial disease, polycystic kidney disease, chronic
 CC or acute renal failure, or inflammatory responses (e.g. asthma,
 CC rheumatoid arthritis, psoriasis or multiple sclerosis) in mammals. The
 CC PRO genes may also be used in gene therapy, particularly for replacing a
 CC defective gene. The sequences presented in ABU64499-ABU64559 are the
 CC PRO polynucleotides of the invention.
 XX
 SQ Sequence 189 AA;
 Query Match 100.0%; Score 1045; DB 24; Length 189;
 Best Local Similarity 100.0%; Pred. No. 5, 3e-86;
 Matches 189; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 MTHRTTMAARRSRATPTCAPAGMPCSRRLPSPSRCSHSACCGDPASTRMKAAPQ 60
 DB 1 MTHRTTMAARRSRATPTCAPAGMPCSRRLPSPSRCSHSACCGDPASTRMKAAPQ 60
 QY 61 PTLGVVPOASVPLTLTDLAOWEPVLPFAHPNASTVYVCTPVPHPPMAALSTPTROIS 120
 DB 61 PTLGVVPOASVPLTLTDLAOWEPVLPFAHPNASTVYVCTPVPHPPMAALSTPTROIS 120
 QY 121 SSDTDPADGSPNPLCCCFHPAFSTLNPVRLFPQEAFFPAHPIYDLQSVSVSPAS 180
 DB 121 SSDTDPADGSPNPLCCCFHPAFSTLNPVRLFPQEAFFPAHPIYDLQSVSVSPAS 180
 QY 181 RGOALRRRAQ 189
 DB 181 RGOALRRRAQ 189
 RESULT 7
 ID ABU54350 standard; Protein; 189 AA.
 XX ABU54350;
 AC
 XX 10-MAR-2003 (first entry)
 DT
 XX Human secreted/transmembrane protein PRO232.
 DE
 XX Human: PRO: secreted protein; transmembrane protein; enterocolitis;
 KW gastrointestinal ulceration; skin disease;
 KW abnormal keratinocyte differentiation; psoriasis; epithelial cancer;
 KW squamous cell carcinoma; Alzheimer's disease; Parkinson's disease;
 KW amyotrophic lateral sclerosis; inflammatory disease;
 KW rheumatoid arthritis; asthma; multiple sclerosis; organ failure;
 KW atherosclerosis; cardiac injury; infertility; birth defect;
 KW premature aging; AIDS; acquired immunodeficiency syndrome; cancer;
 KW diabetic complication; wound repair.
 XX Homo sapiens.

PS Claim 23; Page 111; 132pp; German.

CC This invention describes novel polypeptide fragments (I) and the
 CC polynucleotides (II) that encode them that are highly expressed in a
 CC human bladder tumour and which have cytostatic activity. (II) are used
 CC for recombinant expression of (I) and to isolate complete genes. (I) are
 CC used to identify agents suitable for treatment of bladder cancer, to
 CC directly treat this form of cancer (including expression from gene
 CC therapy vectors) or are used in a preparation for cancer treatment. (I)
 CC is also used for the generation of specific antibodies. (II) are
 CC identified by assembling ESTs (expressed sequence tags) from a
 CC particular tissue type before comparison of expression patterns. This
 CC allows a significantly longer fragment of the gene to be revealed, and
 CC therefore reduces the number of failures associated with the fact that
 CC ESTs from different libraries may represent different parts of the same
 CC unknown gene, distorting the estimated frequency of occurrence in a
 CC particular tissue. AAY6143-Y66198 represent protein fragments encoded by
 CC the human bladder tumour cDNA library derived expressed sequence tag
 CC (EST) fragments represented in AA243260-243309.

CC Sequence 187 AA;

Query Match 95.5%; Score 998; DB 20; Length 187;
 Best Local Similarity 97.8%; Pred. No. 8.7e-82;
 Matches 182; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

OY 4 RTTWARTSRATVPTCATPAGPMPGCSRLPSPSLKSLHSAACSGDPASRYLMGAPLPTL 63
 DB 2 RAAGARTSRATVPTCATPAGPMPGCSRLPSPSLKSLHSAACSGDPASRYLMGAPLPTL 61
 OY 64 GVPQASVPLITDLAOMEPPVLPFAHNPASLTMVTCVPVPHDPDMALSRPTQISSD 123
 DB 62 GVPQASVPLITDLAOMEPPVLPFAHNPASLTMVTCVPVPHDPDMALSRPTQISSD 121
 OY 124 TDPPADGSPNPLCCCFHGPASTLNPYLRLHLPQEAFAHPIYDLSQVSVSPAPSGQ 183
 DB 122 TDPPADGSPNPLCCCFHGPASTLNPYLRLHLPQEAFAHPIYDLSQVSVSPAPSGQ 181
 OY 184 ALPRAQ 189
 DB 182 ALPRAQ 187

RESULT 9

ABU18375
 ID ABU18375 standard; Protein; 1518 AA.

AC ABU18375;

DT 30-JAN-2003 (first entry)

DE Breast specific related amino acid sequence SEQ ID NO 184.

KW Cytostatic; BSP-agonist; BSP-antagonist; vaccine; gene therapy; cancer;

KM metastatic; breast cancer; breast specific; human.

OS Homo sapiens.

PN MO200277232-A2.

PD 03-OCT-2002.

PF 21-NOV-2001; 2001MO-US43815.

PR 22-NOV-2000; 2000US-252509P.

PA (DIAD-) DIADEXUS INC.

PI Salceda S, Macina RA, Recipon H, Pluta J, Sun Y, Liu C;

DR WPI; 2003-018927/01.

PT New isolated nucleic acid molecule, useful for treating breast cancer.

PT and diagnosing or monitoring the presence of metastases of breast
 PT cancer in a patient

PS Claim 11; Page 313-320; 377pp; English.

CC The invention relates to a novel isolated nucleic acid molecule
 CC comprising: a sequence encoding a sequence comprising 11-1518 amino
 CC acids; a sequence comprising 190-8144 bp; or a sequence that selectively
 CC hybridises to, or having at least 60% identity with the 11-1518 amino
 CC acid or 190-8144 nt sequence. The polypeptide and the nucleic acid are
 CC useful for treating breast cancer and diagnosing or monitoring the
 CC presence of metastases of breast cancer in a patient. The polynucleotides
 CC of the invention can be used to treat disorders by gene therapy. This
 CC sequence represents a breast specific related polypeptide of the
 CC invention.

CC Sequence 1518 AA;

Query Match 11.4%; Score 119; DB 24; Length 1518;
 Best Local Similarity 28.9%; Pred. No. 0.072;
 Matches 56; Conservative 19; Mismatches 79; Indels 40; Gaps 8;

OY 3 HRTTWARTSRATVPTCATPAGPMPGCSRLPSPSLKSLHSAACSGDPASRYLMGAPL 59
 DB 744 HRTTPSRPSRPSQSVSRPSRPSRPLHPCPPQAPPTL-----PGIF-----VI 786
 OY 60 OPTLGVPQASVPLITDLAOMEPPVLPFAHNPASLTMVTCVPVPHDPDMALSRPTQOI 119
 DB 787 ONQGVPPASNPAPATAGCPQPPLRPOSQPEG-----PLP-PAVHLPPSSSTSSAVA 838
 OY 120 SSSDTP--PADGPN-----PLCCFHGPASTLNPYLRLHLPQEAFAHPIYDLSQV 171
 DB 839 SSSERSRLPAPTPSDFLQFP-----SQGHKSPPTLHIVEPAAPPPPTPTQM 894
 OY 172 MSVSPAPSRQAL 185
 DB 895 VTTPPALPQPKAL 908

RESULT 10

ABU53162
 ID ABU53162 standard; Protein; 277 AA.

AC ABU53162;

DT 14-APR-2003 (first entry)

DE Human testes-derived DKFZphes3_2a11 homologue #22.

KW Human; gene therapy; vaccine; disease treatment; detection.

OS Homo sapiens.

PN MO200112659-A2.

PD 22-FEB-2001.

PF 18-AUG-2000; 2000MO-IB01496.

PR 18-AUG-1999; 99US-0149499.

PR 28-SEP-1999; 99US-0156503.

PA (GERH-) GERMAN HUMAN GENOME PROJECT.

PI Wiemann S;

DR WPI; 2001-327840/34.

PT Nucleic acids having the sequences of clones isolated from libraries of
 PT different human tissues, useful in recombinant DNA methodologies -

PS Example III; Page 775; 1095pp; English.

123 D D P F A D G S N P L C C C F H G P A F S I L N P V L R H L F P Q E A F P A H P I Y D L S Q W S V S P A P 179

ABU53160;

DT 14-APR-2003 (first entry)

Human testes-derived DKFzphtes3_2a11 homologue #20

Human; gene therapy; vaccine; disease treatment; detection.

OS Homo sapiens.

PN WO200112659-A2.

PD 22-FEB-2001

PF 18-AUG-2000; 2000WO-IB01496.

PR 18-AUG-1999; 99US-0149499.

PR 28-SEP-1999; 99US-0156503.

PA (GEHU-) GERMAN HUMAN GENOME PROJECT.

PI Wiemann S;

WPI; 2001-327840/34.

PT Nucleic acids having the sequences of clones isolated from libraries of
PR different human tissues, useful in recombinant DNA methodologies -
IV

PS Example III; Page 774-775; 1095pp; English.

This invention describes novel polynucleotides and polypeptides isolated from human cDNA libraries which can be used for gene therapy or in vaccines. The polynucleotides of the invention and antibodies encoded by them may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate polypeptide expression. The products of the invention may also be used to identify modulators of expression and activity and to down regulate expression and activity. The antibodies of the invention may also be used as diagnostic agents for detecting the presence of polypeptides in samples. This sequence represents a homologue of a polypeptide described in the disclosure of the invention.

SQ Sequence 395 AA;

Query Match	11.2%	Score 117.5;	DB 22;	Length 395;
...

Best Local Similarity 23.28; Pred. No. 0.022;

Matches 41; Conservative 23; Mismatches 98; Indels 15; Gaps 5;

QY 5 TTTWARTSRAVTPTCATPAGPMPCSRLPPSLRCSLHSACCSGDPASYRLMGAPLQPTLG 64

Db 165 TTPSPPTTPTTPSPPTTPTTPSPPTITPTTPPPPTTPSPPTTPTTPP--PTPTT 222

65. VVPQASVPLL--TDLAQWEPVLVPEAHPNASLTMVCTPVPHPPDPMALSRTPTRQISSS 122

Db 223 PSPPTTTPITPPPTSTTTLLPPTTTPSPPPPTTPTTTP--PPPTTTPSP--TTTTPSPPTTTT 277

02Y 123 DTDPADGSPNPLCCCFHGPAFSTLNPVLRHLEPQEAFFPAHPYDLSQVSVSPAP 179

Db 278 TTPPTTTTSSSPIITTTTSPSPPTTTMTTP-----SPTTTTPSSSPIITTTTTPSSSTTTTTPSP 328

Search completed: September 24, 2003, 18:08:53

Job time : 43 secs

ID AAY66174 standard; Protein; 187 AA.

XX
AC AAY66174:

DT 14-FEB-2000 (first entry).

XX
DE Human bladder tumour EST encoded protein 32.
XX

XX Expressed sequence tag; human; bladder; tumour; cancer; cytostatic;
KW treatment; gene therapy; EST.

XX
OS Homo sapiens.

XX
PN DE19818619-A1.

XX
PD 28-OCT-1999.

XX
PF 21-APR-1998; 98DE-1018619.

XX
PR 21-APR-1998; 98DE-1018619.

XX
PA (META-) METAGEN GES GENOMFORSCHUNG MBH.

XX
PI Rosenthal A, Specht T, Hinzmann B, Schmitt A, Pilarsky C, Dahl E;
XX

XX
DR WPI; 1999-612028/53.

XX New nucleic acid sequences expressed in bladder tumor tissue, and
PT derived polypeptides, for treatment of bladder tumor and identification
PT of therapeutic agents -

PS Claim 23; Page 111; 132pp; German.
yy

This invention describes novel polypeptide fragments (I) and the polynucleotides (II) that encode them that are highly expressed in a human bladder tumour and which have cytostatic activity. (II) are used for recombinant expression of (I) and to isolate complete genes. (I) are used to identify agents suitable for treatment of bladder cancer, to directly treat this form of cancer (including expression from gene therapy vectors) or are used in a preparation for cancer treatment. (I) is also used for the generation of specific antibodies. (II) are identified by assembling ESTs (expressed sequence tags) from a particular tissue type before comparison of expression patterns. This allows a significantly longer fragment of the gene to be revealed, and therefore reduces the number of failures associated with the fact that ESTs from different libraries may represent different parts of the same unknown gene, distorting the estimated frequency of occurrence in a particular tissue. AAY66143-Y66198 represent protein fragments encoded by the human bladder tumour cDNA library derived expressed sequence tag (EST) fragments represented in AA243260-243309.

SQ Sequence 187 AA;

Query Match

Best Local Similarity 97.88; Score 998; DB 20; Length 187;

Matches 182; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

```

QY      4 RTTTWARRTSRAVTPTCATPAGMPMCSRLLPPLSLRSLHSACCSGDPASYRLWGAPLQPTL 63
Db      |
        2 RAARGARRTSRAVTPTCATPAGMPMCSRLLPPLSLRSLHSACCSGDPASYRLWGAPLQPTL 61
QY      64 GVPVQASVPLLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHDPDPMALSRTPTRQISSSD 123
Db      |
        62 GVPVQASVPLLLTDLAQWEPVLVPEAHPNASLTMYVCTPVPHDPDPMALSRTPTRQISSSD 121
QY      124 TDPPADGPSNPLCCCFHGFAPFSTLNPVLRHLFPQEAFFAHPHYDLSQVWSVVSAPPSRGQ 183
Db      |
        122 TDPPADGPSNPLCCCFHGFAPFSTLNPVLRHLFPQEAFFAHPHYDLSQVWSVVSAPPSRGQ 181
QY      184 ALRRQAQ 189
Db      |
        182 ALRRQAQ 187

```